Achilles Therapeutics Logo RGB Small.jpg
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
May 22, 2024 07:00 ET | Achilles Therapeutics PLC
Research collaboration combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform
treos logo.jpg
Treos Bio to Present New Clinical Data on Off-the-Shelf Peptide Immunotherapy for Colorectal Cancer at 2024 ASCO Annual Meeting
May 08, 2024 07:45 ET | Treos Bio Corp.
LONDON and BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said...
Promising Personaliz
Promising Personalized Approach to Liver Cancer Therapy Made Possible by DNA-based Neoantigen Research Designed at The Wistar Institute
April 30, 2024 10:18 ET | The Wistar Institute
PHILADELPHIA, PA, April 30, 2024 (GLOBE NEWSWIRE) -- Hepatocellular carcinoma (HCC), or liver cancer, is an aggressive malignancy with limited treatment options. An immunologically cold cancer —...
Angelini Ventures Logo clear background.png
Angelini Ventures invests into extended €75.8 million ($82 million) Series C financing round for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer vaccines
March 21, 2024 03:00 ET | Angelini Ventures
Angelini Ventures joins syndicate of top-tier international healthcare investors in Nouscom’s Series C financing roundFinancing will enable Nouscom to continue advancing the clinical development of...
BioNTech präsentiert
BioNTech präsentiert auf der AACR-Jahrestagung 2024 klinische Daten-Updates zu mRNA-basierten und zielgerichteten Onkologie-Kandidaten
March 11, 2024 07:45 ET | BioNTech SE
MAINZ, Deutschland, 11. März 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird auf der diesjährigen Jahrestagung der American Association for Cancer Research („AACR“), die vom...
BioNTech to Present
BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024
March 11, 2024 07:45 ET | BioNTech SE
MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association...
GeoVax Announces Multiple Patent Issuances and Allowances
February 13, 2024 09:00 ET | GeoVax, Inc.
Intellectual Property Assets Strengthened for Cancer Immunotherapy Programand for Marburg Virus and HIV Vaccines ATLANTA, GA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....
Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
January 04, 2024 08:00 ET | Enara bio
Licensed antigens are shared across major subsets of NSCLC and have confirmed presence on the surface of tumor cells, homogeneous expression within tumors, and strong immunogenicityBoehringer...
Emergen logo.png
Cancer Vaccine Market Size Worth USD 21.39 Billion in 2032 | Emergen Research
January 02, 2024 08:03 ET | Emergen Research
Vancouver, Jan. 02, 2024 (GLOBE NEWSWIRE) -- The global cancer vaccine market demonstrated a robust USD 7.31 Billion in 2022, with expectations of a substantial CAGR of 10.9% throughout the forecast...
New Logo.png
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
December 18, 2023 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Trademark Office (USPTO) has allowed patent application 17/488,430, titled...